Worldwide Next Generation Sequencing Industry to 2025 - Competitive Analysis and the Impact of COVID-19

News provided by

Jun 17, 2021, 17:00 ET

DUBLIN, June 17, 2021 /PRNewswire/ -- The "Global Next Generation Sequencing Market (2020-2025) by Type, Applications, Technology, End user, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

The Global Next Generation Sequencing Market is estimated to be USD 9.51 Bn in 2020 and is expected to reach USD 25.28 Bn by 2025, growing at a CAGR of 21.6%.

The major factors such as increasing research and development activities utilizing the NGS technologies, growing applications of NGS in clinical diagnosis, and discovery applications demanding NGS technology are expected to drive the growth of the overall market. The rapid speed, cost, and accuracy of the NGS technology have also helped in the growth of the market. However, the current market is facing challenges due to the difficulty in the management of large data and complications associated with Big Data management.

Recent Developments
1. In September 2020, Illumina Inc. acquired GRAIL, a healthcare company focused on multi-cancer early detection, for cash and stock consideration of USD 8 billion upon closing of the transaction.
2. In August 2020, Guardant Health Inc. received the United States Food and Drug Administration (FDA) approval for Guardant360 CDx, the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor).
3. In 2019, Qiagen launched NGS panels and liquid biopsy solutions with integrated bioinformatics to lead advances in cancer research.

Company Profiles

Some of the companies covered in this report are 10x Genomics, 454 Life Sciences Corporation (Roche Holding AG), Agilent Technologies Inc., Beijing Genomics Institute, Bio matters Ltd., Bio-Rad Laboratories Inc., DNASTAR Inc., Eurofins Scientific, F. Hoffmann-La Roche AG, GATC Biotech AG., GenapSys Inc., Qiagen N.V., Thermo Fisher Scientific Inc., etc.

Competitive Quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

The report offers a comprehensive evaluation of theGlobal Next Generation Sequencing Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
The report also contains the competitive analysis using the Competitive Quadrant, the analyst's proprietary competitive positioning tool.

Report Highlights

A complete analysis of the market, including parent industry
Important market dynamics and trends
Market segmentation
Historical, current, and projected size of the market based on value and volume
Market shares and strategies of key players
Recommendations to companies for strengthening their foothold in the market

Key Topics Covered:

1 Report Description

2 Research Methodology

3 Executive Summary

4 Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Increasing Applications in Clinical Diagnosis
4.2.1.2 Speed, Cost, and Accuracy
4.2.1.3 Efficient Replacement for Traditional Technologies (Microarrays)
4.2.1.4 Increasing need of inexpensive sequencing devices in routine medical checkups and clinical settings
4.2.2 Restraints
4.2.2.1 Standardization concerns over NGS based diagnostics
4.2.2.2 Lack of skilled professionals
4.2.2.3 Huge data processing and reimbursement uncertainty in clinical settings
4.2.3 Opportunities
4.2.3.1 Lucrative opportunities in emerging markets
4.2.3.2 Potential significance of NGS analysis in identifying cancer mutations
4.2.3.3 Investigate NGS use to enable single-cell genomics
4.2.4 Challenges
4.2.4.1 Data analysis and bioinformatics challenges
4.3 Trends

5 Market Analysis
5.1 Porter's Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis

6 Global Next Generation Sequencing Market, By Type
6.1 Introduction
6.2 Whole genome sequencing
6.3 Exome sequencing
6.4 Targeted sequencing
6.5 Others

7 Global Next Generation Sequencing Market, By Application
7.1 Introduction
7.2 Research application
7.3 Clinical application
7.4 Others

8 Global Next Generation Sequencing Market, By Technology
8.1 Introduction
8.2 Sequencing by synthesis
8.3 Ion semiconductor sequencing
8.4 Others

9 Global Next Generation Sequencing Market, By End User
9.1 Introduction
9.2 Academic institutes & research centres
9.3 Hospitals & clinics
9.4 Pharmaceutical & biotechnology companies
9.5 Others

10 Global Next Generation Sequencing Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 South America
10.3.1 Brazil
10.3.2 Argentina
10.4 Europe
10.4.1 UK
10.4.2 France
10.4.3 Germany
10.4.4 Italy
10.4.5 Spain
10.4.6 Rest of Europe
10.5 Asia-Pacific
10.5.1 China
10.5.2 Japan
10.5.3 India
10.5.4 Indonesia
10.5.5 Malaysia
10.5.6 South Korea
10.5.7 Australia
10.5.8 Russia
10.5.9 Rest of APAC
10.6 Rest of the World
10.6.1 Qatar
10.6.2 Saudi Arabia
10.6.3 South Africa
10.6.4 United Arab Emirates
10.6.5 Latin America

11 Competitive Landscape
11.1 Competitive Quadrant
11.2 Market Share Analysis
11.3 Competitive Scenario
11.3.1 Mergers & Acquisitions
11.3.2 Agreement, Collaborations, & Partnerships
11.3.3 New Product Launches & Enhancements
11.3.4 Investments & Funding

12 Company Profiles
12.1 10x Genomics
12.2 454 Life Sciences Corporation (Roche Holding AG)
12.3 Agilent Technologies Inc.
12.4 Beijing Genomics Institute
12.5 Bio matters Ltd.
12.6 Bio-Rad Laboratories Inc.
12.7 DNASTAR Inc.
12.8 Eurofins Scientific
12.9 F. Hoffmann-La Roche AG
12.10 GATC Biotech AG.
12.11 GenapSys Inc.
12.12 GENEWIZ
12.13 Genomatix GmbH
12.14 Illumina Inc.
12.15 Macrogen Inc.
12.16 Myriad Genetics Inc.
12.17 New England Biolabs Inc.
12.18 NuGEN Technologies Inc.
12.19 Oxford Nanopore Technologies Limited
12.20 Pacific Biosciences of California Inc.
12.21 Partek Inc.
12.22 PerkinElmer Inc.
12.23 PierianDx.
12.24 Qiagen N.V.
12.25 Thermo Fisher Scientific Inc.

13 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/y1r62j

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets